


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 represents $-C_{1-6}$ alkyl- $O-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, aryl, heterocyclyl, heteroaryl, $-C_{1-6}$ alkyl-aryl, $-C_{1-6}$ alkyl-heteroaryl, $-C_{1-6}$ alkyl-heterocyclyl, -aryl-X-aryl, -aryl-X-heteroaryl, -aryl-X-heterocyclyl, -heteroaryl-X-aryl, -heteroaryl-X-heteroaryl, -heteroaryl-X-heterocyclyl, -heterocyclyl-X-aryl, -heterocyclyl-X-heteroaryl, or -heterocyclyl-X-heterocyclyl,

wherein said C_{1-6} alkyl, C_{3-8} cycloalkyl, aryl, heteroaryl, and heterocyclyl groups of R^1 may be optionally substituted by one or more (~~eg. 1, 2 or 3~~) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, halo C_{1-6} alkyl, polyhalo C_{1-6} alkyl, halo C_{1-6} alkoxy, polyhalo C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonyl C_{1-6} alkyl, C_{1-6} alkylsulfonamido C_{1-6} alkyl, C_{1-6} alkylamido C_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, aryloxy, arylsulfonamido, arylcarboxamido, aroyl, or a group $NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-NR^{15}SO_2R^{16}$, and ~~or~~ $-SO_2NR^{15}R^{16}$, wherein R^{15} and R^{16} independently represent hydrogen or C_{1-6} alkyl or together form a heterocyclic ring;

X represents a bond, O, CO, OCH_2 , CH_2O , or SO_2 ;

Z represents CO, $CONR^{10}$, or SO_2 ;

R^{10} represents hydrogen, C_{1-6} alkyl, $-C_{3-8}$ cycloalkyl, aryl, heterocyclyl, or heteroaryl;


--- represents a single or a double bond;

m and n independently represent 0, 1, or 2;

R^2 represents hydrogen, C_{1-6} alkyl, or C_{1-6} alkoxy;

R^3 represents halogen, C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, cyano, amino, $-COC_{1-6}$ alkyl, $-SO_2C_{1-6}$ alkyl, or trifluoromethyl;

R^4 represents $-(CH_2)_q-NR^{11}R^{12}$ or a group of formula (i):



wherein q is 2, 3, or 4;

-NR¹¹R¹² represents a heterocyclic group optionally substituted by one or more (eg. 1, 2 or 3) R¹⁷ groups;

R¹³ represents C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-C₁₋₆ alkoxy, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl;

R¹⁴ and R¹⁷ independently represent halogen, C₁₋₆ alkyl, haloalkyl, OH, or C₁₋₆ alkoxy;

f is 0 or 1;

g is 1 or 2

k is 0, 1, or 2

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound as defined in claim 1 wherein R¹ represents:

-aryl optionally substituted by 1 or 2 halogen, haloC₁₋₆ alkyl, cyano or SO₂Me groups;

-aryl-X-heterocyclyl;

-heteroaryl optionally substituted by 1 or 2 haloC₁₋₆ alkyl or cyano groups;


-heterocyclyl optionally substituted by 1 or 2 oxo groups; or

-C₁₋₆ alkyl-O-C₁₋₆ alkyl.

3. (Currently Amended) A compound as defined in claim 2 wherein R¹ represents tetrahydropyranyl, 4-cyanophenyl, 2-cyanopyridin-3-yl, or 2-trifluoromethylpyridin-3-yl.

4. (Original) A compound as defined in claim 3 wherein R¹ represents 4-cyanophenyl.

5. (Currently Amended) A compound as defined in ~~any one of claims 1 to 4~~ claim 1 wherein X and Z both represent CO.

6. (Currently Amended) A compound as defined in ~~any one of claims 1 to 5~~ claim 1 wherein  represents a single bond.

7. (Currently Amended) A compound as defined in ~~any one of claims 1 to 6~~ claim 1 wherein m and n both represent 0.

8. (Currently Amended) A compound as defined in ~~any one of claims 1 to 7~~ claim 1 wherein R⁴ represents -(CH₂)_q-NR¹¹R¹², q represents 3 and -NR¹¹R¹² represents N-piperidinyl or N-pyrrolidinyl optionally substituted by 1 or 2 C₁₋₆

alkyl groups; or wherein R⁴ represents a group of formula (i) wherein f and k both represent 0, g represents 2, and R¹³ represents C₁₋₆ alkyl or C₃₋₈ cycloalkyl.

9. (Original) A compound as defined in claim 8 wherein R⁴ represents a group of formula (i) wherein f and k both represent 0, g represents 2 and R¹³ represents i-propyl.

10. (Original) A compound as defined in claim 1 which is:

4-(4-([3-(1-Piperidinyl)propyl]oxy)phenyl)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidine;
4-([4-(4-([3-(1-Piperidinyl)propyl]oxy)phenyl)-1-piperidinyl]carbonyl)benzonitrile;
4-([4-(4-([3-(1-Piperidinyl)propyl]oxy)phenyl)-1-piperidinyl]carbonyl)pyridine;
4-(4-([3-(1-Piperidinyl)propyl]oxy)phenyl)-1-([4-(1-pyrrolidinylcarbonyl)phenyl]carbonyl) piperidine;
1-([4-(Methylsulfonyl)phenyl]carbonyl)-4-(4-([3-(1-piperidinyl) propyl] oxy) phenyl) piperidine;
1-([4-Fluorophenyl]carbonyl)-4-(4-([3-(1-piperidinyl)propyl]oxy)phenyl)piperidine;
3-([4-(4-([3-(1-Piperidinyl)propyl]oxy)phenyl)-1-piperidinyl]carbonyl)pyridine;
4-([4-(4-([3-(1-Piperidinyl)propyl]oxy)phenyl)-1-piperidinyl]carbonyl)morpholine;
1-(1-Piperidinylcarbonyl)-4-(4-([3-(1-piperidinyl)propyl]oxy)phenyl)piperidine;
4-(4-([3-(1-Piperidinyl)propyl]oxy)phenyl)-1-(1-pyrrolidinylcarbonyl)piperidine;
1-(4-Fluoro-phenyl)-1-{4-[4-(1- isopropyl-piperidin-4-yloxy)-phenyl]-piperidin-1-yl}- methanone;
1-(1-Methylethyl)-4-([4-(1-([4-(1-pyrrolidinylcarbonyl)phenyl]carbonyl)-4-piperidinyl)phenyl]oxy)piperidine;
1-(1-Methylethyl)-4-([4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-4-piperidinyl]phenyl]oxy)piperidine;
1-(1-Methylethyl)-4-([4-(1-([4-(methylsulfonyl)phenyl]carbonyl)-4-piperidinyl)phenyl]oxy)piperidine;
1-(1-Methylethyl)-4-([4-[1-[3-(methyloxy)propanoyl]-4-piperidinyl]phenyl]oxy)piperidine;
4-([4-(4-([1-(1-Methylethyl)-4-piperidinyl]oxy)phenyl)-1-piperidinyl]carbonyl)pyridine;
3-([4-(4-([1-(1-Methylethyl)-4-piperidinyl]oxy)phenyl)-1-piperidinyl]carbonyl)pyridine;
4-([4-(4-([1-(1-Methylethyl)-4-piperidinyl]oxy)phenyl)-1-piperidinyl]carbonyl)morpholine;
1-(1-Azetidinylcarbonyl)-4-(4-([1-(1-methylethyl)-4-piperidinyl]oxy)phenyl)piperidine;
1-(1-Methylethyl)-4-([4-[1-(1-pyrrolidinylcarbonyl)-4-piperidinyl]phenyl]oxy)piperidine;

1-(1-Methylethyl)-4-({4-[1-(1-piperidinylcarbonyl)-4-piperidinyl]phenyl}oxy)piperidine;
4-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-piperidinyl} carbonyl}thiomorpholine 1,1-dioxide;
4-{{4-(4-{{1-(1-Cyclobutyl-4-piperidinyl)oxy} phenyl}-1-piperidinyl)carbonyl} benzonitrile;
1-Cyclobutyl-4-{{4-{{1-{{4-(4-fluorophenyl) carbonyl}-4-piperidinyl}phenyl) oxy} piperidine;
1-Cyclobutyl-4-{{4-{{1-{{4-(1-pyrrolidinylcarbonyl)phenyl}carbonyl}-4-piperidinyl}phenyl}oxy}piperidine;
1-Cyclobutyl-4-{{4-{{1-{{3-(methyloxy) propanoyl}-4-piperidinyl} phenyl}oxy} piperidine;
4-{{4-(4-{{1-(1-Cyclobutyl-4-piperidinyl)oxy} phenyl}-1-piperidinyl)carbonyl}pyridine;
3-{{4-(4-{{1-(1-Cyclobutyl-4-piperidinyl)oxy}phenyl}-1-piperidinyl)carbonyl}pyridine;
4-{{4-(4-{{1-(1-Cyclobutyl-4-piperidinyl)oxy}phenyl}-1-piperidinyl)carbonyl}morpholine;
1-{{4-(4-Fluorophenyl)carbonyl}-4-(4-{{3-(1-piperidinyl)propyl}oxy}phenyl)-1,2,3,6-tetrahydropyridine;
4-{{4-(4-{{3-(1-Piperidinyl)propyl}oxy} phenyl)-3,6-dihydro-1(2H)-pyridinyl} carbonyl} benzonitrile;
4-(4-{{3-(1-Piperidinyl)propyl} oxy}phenyl)-1-{{4-(1-pyrrolidinylcarbonyl)phenyl}carbonyl}-1,2,3,6-tetrahydropyridine;
4-(4-{{3-(1-Piperidinyl)propyl} oxy} phenyl)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridine;
1-{{4-(4-(Methylsulfonyl)phenyl)carbonyl}-4-(4-{{3-(1-piperidinyl)propyl}oxy} phenyl)-1,2,3,6-tetrahydropyridine;
4-{{4-(4-{{3-(1-Piperidinyl)propyl}oxy}phenyl)-3,6-dihydro-1(2H)-pyridinyl}carbonyl} morpholine;
1-(1-Piperidinylcarbonyl)-4-(4-{{3-(1-piperidinyl)propyl}oxy}phenyl)-1,2,3,6-tetrahydropyridine;
4-(4-{{3-(1-Piperidinyl)propyl}oxy} phenyl)-1-(1-pyrrolidinylcarbonyl)-1,2,3,6-tetrahydropyridine;
1-{{4-(4-Fluorophenyl)carbonyl}-4-(4-{{1-(1-methylethyl)-4-piperidinyl}oxy}phenyl)-1,2,3,6-tetrahydropyridine;
4-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-3,6-dihydro-1(2H)-pyridinyl}carbonyl}benzonitrile;
4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-{{4-(1-pyrrolidinylcarbonyl)phenyl}carbonyl}-1,2,3,6-tetrahydropyridine;
4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy} phenyl)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridine;
4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-{{4-(4-(methylsulfonyl)phenyl)carbonyl}-1,2,3,6-tetrahydropyridine;

4-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-3,6-dihydro-1(2H)-pyridinyl}carbonyl}pyridine;
4-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-3,6-dihydro-1(2H)-pyridinyl}carbonyl}morpholine;
4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-(1-piperidinylcarbonyl)-1,2,3,6-tetrahydropyridine;
4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-(1-pyrrolidinyl carbonyl)-1,2,3,6-tetrahydropyridine;
4-{{4-(4-{{3-{{(2R)-2-Methyl-1-pyrrolidinyl}propyl}oxy}phenyl)-1-piperidinyl}carbonyl}benzonitrile;
4-{{4-(4-{{3-{{(2R)-2-Methyl-1-pyrrolidinyl}propyl}oxy}phenyl)-1-(tetrahydro-2H-pyran-4-ylcarbonyl}piperidine;
4-{{4-(4-{{3-{{(2R,5R)-2,5-Dimethyl-1-pyrrolidinyl}propyl}oxy}phenyl)-1-(tetrahydro-2H-pyran-4-ylcarbonyl}piperidine;
2-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-piperidinyl}carbonyl}pyrazine;
3-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-piperidinyl}carbonyl}benzonitrile;
1-(1-Methylethyl)-4-{{4-(1-{{4-(trifluoromethyl)phenyl}carbonyl}-4-piperidinyl)phenyl}oxy}piperidine;
6-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-piperidinyl}carbonyl}quinoxaline;
or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) A compound as defined in claim 1 which is:
5-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-piperidinyl}carbonyl}-2-pyridinecarbonitrile; and
5-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-piperidinyl}carbonyl}-2-(trifluoromethyl)pyridine;
or a pharmaceutically acceptable salt thereof.

12. (Original) A compound as defined in claim 1 which is:
4-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-piperidinyl}carbonyl}benzonitrile or a pharmaceutically acceptable salt thereof.

13. (Currently Amended) A pharmaceutical composition which comprises the compound of formula (I) as defined in ~~any one of claims 1 to 12~~ claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

14. (Cancelled).

15. (Cancelled).


16. (Cancelled).

17. (Currently Amended) A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in ~~any one of claims 1 to 12~~ claim 1 or a pharmaceutically acceptable salt thereof.

18. (Cancelled).

19. (Original) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) preparing a compound of formula (I) wherein Z represents CO which comprises reacting a compound of formula (II)



or an optionally activated or protected derivative thereof, wherein ~~---~~, R^2 , R^3 , R^4 , m and n are as defined in claim 1, with a compound of formula $R^1\text{-CO-L}^1$, wherein R^1 is as defined in claim 1 and L^1 represents a suitable leaving group such as a suitable halogen atom, or a hydroxyl group; or

(b) preparing a compound of formula (I) wherein Z represents SO_2 which comprises reacting a compound of formula (II), with a compound of formula $R^1\text{-SO}_2\text{-L}^2$, wherein R^1 is as defined in claim 1 and L^2 represents a suitable leaving group, such as a suitable halogen atom (eg. chlorine); or

(c) preparing a compound of formula (I) wherein Z represents CONH which comprises reacting a compound of formula (II), with a compound of formula $R^1\text{-N=C=O}$, wherein R^1 is as defined in claim 1; or

(d) preparing a compound of formula (I) wherein Z represents CONR^{10} which comprises reacting a compound of formula (II), with a compound of formula $R^1\text{R}^{10}\text{N-L}^3$, wherein R^1 and R^{10} are as defined in claim 1 and L^3 represents hydrogen or COCl ; or

(e) deprotecting a compound of formula (I) or converting groups which are protected; and optionally thereafter

(f) interconversion to other compounds of formula (I).